NTRK1 and gastrointestinal stromal tumor: Crenolanib is a potent class III receptor tyrosine kinase inhibitor including PDGFRB, with minimal toxicity, whose therapeutic efficacy has already been validated through clinical trials in GIST and human acute myeloid leukemia.